Thomsons

Capital Markets

Partner

Emma acts for clients in health, life sciences, biotechnology, technology, agriculture, infrastructure, retail and manufacturing sectors. Her practice includes cross-border transactions with an Asia focus, particularly involving clients in Hong Kong, Singapore, the People's Republic of China and Indonesia.

Emma advises on equity and debt capital markets, mergers and acquisitions, private equity and corporate advisory. She provides clients with access to high-level skills in areas that are heavily regulated and highly technical, spanning the full transaction lifecycle from structuring through to execution and governance.

Emma has advised Microba Life Sciences on its ASX listing, raising A$30 million (reflected in a client testimonial from CEO Luke Reid describing the team as the most pragmatic legal firm he has worked with over his career). She has also acted on the QBiotics Group A$130 million merger via dual schemes of arrangement consolidating QBiotics Limited and EcoBiotics Limited, and on the Cronos Australia merger with CDA Health. Her practice spans the full range of capital markets and M&A complexity in highly regulated sectors including life sciences and biotechnology.

Emma's combination of technical capital markets expertise with deep sector knowledge in health and life sciences, and her cross-border Asia-Pacific capability, positions her as a specialist in regulated sector transactions.